BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winning BTK inhibitor to fight certain blood cancers.